Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives
暂无分享,去创建一个
[1] L B Sheiner,et al. Pharmacokinetic and pharmacodynamic modeling in vivo. , 1981, Critical reviews in bioengineering.
[2] M W Fischman,et al. Kinetics of cocaine distribution, elimination, and chronotropic effects , 1985, Clinical pharmacology and therapeutics.
[3] C. T. Viswanathan,et al. Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development , 1992, Clinical pharmacology and therapeutics.
[4] S. Tunn,et al. Receptor‐Based Pharmacokinetic‐Pharmacodynamic Analysis of Corticosteroids , 1993, Journal of clinical pharmacology.
[5] R B Smith,et al. Pharmacodynamic Modelling , 1991, Clinical pharmacokinetics.
[6] D R Stanski,et al. Population pharmacodynamic model for ketorolac analgesia , 1996, Clinical pharmacology and therapeutics.
[7] B. Plaud,et al. Population pharmacokinetic‐pharmacodynamic analysis of fluindione in patients , 1998, Clinical pharmacology and therapeutics.
[8] H Derendorf,et al. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.
[9] Richard P. Lewis,et al. Pharmacokinetics of digoxin: Relationship between response intensity and predicted compartmental drug levels in man , 1979, Journal of Pharmacokinetics and Biopharmaceutics.
[10] L B Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models , 1986, Clinical pharmacology and therapeutics.
[11] Thomas Layloff,et al. Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic Studies , 1992 .
[12] M Wakelkamp,et al. The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide. , 1998, British journal of clinical pharmacology.
[13] G Levy,et al. Kinetics of drug action: an overview. , 1986, The Journal of allergy and clinical immunology.
[14] Richard R. Almon,et al. Third-generation model for corticosteroid pharmacodynamics: Roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver , 1995, Journal of Pharmacokinetics and Biopharmaceutics.
[15] H. Derendorf,et al. Handbook of Pharmacokinetic/Pharmacodynamic Correlation , 1995 .
[16] G. Segre,et al. Kinetics of interaction between drugs and biological systems. , 1968, Il Farmaco; edizione scientifica.
[17] W. Colburn. Selecting and Validating Biologic Markers for Drug Development , 1997, Journal of clinical pharmacology.
[18] L B Sheiner,et al. Population pharmacokinetics/dynamics. , 1992, Annual review of pharmacology and toxicology.
[19] C. van Boxtel,et al. Kinetics of drug effects in man. , 1988, Therapeutic drug monitoring.
[20] W. Colburn. Pharmacokinetic/pharmacodynamic modeling: What it is! , 1987, Journal of Pharmacokinetics and Biopharmaceutics.
[21] L B Sheiner,et al. Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics with a Nonparametric Pharmacodynamic Model , 1984, Clinical pharmacology and therapeutics.
[22] G. Levy. Kinetics of drug action in man. , 2009, Acta pharmacologica et toxicologica.
[23] D. Shindler,et al. A Pharmacokinetic—Pharmacodynamic Model of d‐Sotalol Q‐Tc Prolongation During Intravenous Administration to Healthy Subjects , 1997, Journal of clinical pharmacology.
[24] W. Colburn,et al. Surrogate Biochemical Markers: Precise Measurement for Strategic Drug and Biologics Development , 1995, Journal of clinical pharmacology.
[25] W. Colburn,et al. Efficacy Measures: Surrogates or Clinical Outcomes? , 1996, Journal of clinical pharmacology.
[26] G Levy,et al. Multicompartment pharmacokinetic models and pharmacologic effects. , 1969, Journal of pharmaceutical sciences.
[27] G. Levy,et al. Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.
[28] W J Jusko,et al. Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.
[29] G Levy,et al. Mechanism‐based pharmacodynamic modeling , 1994, Clinical pharmacology and therapeutics.
[30] France Mentré,et al. The Use of Population Pharmacokinetics in Drug Development , 1996, Clinical pharmacokinetics.
[31] Johan Gabrielsson,et al. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration , 1996, Clinical pharmacology and therapeutics.
[32] Varun Garg,et al. Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[33] Wayne A. Colburn,et al. Simultaneous pharmacokinetic and pharmacodynamic modeling , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[34] W. Gentry,et al. A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[35] E. Chan,et al. Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic‐pharmacodynamic model , 1994, Clinical pharmacology and therapeutics.
[36] M Davidian,et al. Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography. , 1994, Biometrics.
[37] R. Koopmans,et al. Pharmacodynamic modelling of the drug-induced downregulation of a β2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone , 2004, European Journal of Clinical Pharmacology.
[38] H. Möllmann,et al. Pharmacokinetic/Dynamic Correlation of Pulmonary and Cardiac Effects of Fenoterol in Asthmatic Patients After Different Routes of Administration , 1992, Pharmaceutical Research.
[39] J. Wagner,et al. Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. , 1968, Journal of theoretical biology.
[40] A. Racine‐Poon,et al. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti‐immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis , 1997, Clinical pharmacology and therapeutics.
[41] L. Sheiner,et al. Further notes on physiologic indirect response models , 1995, Clinical pharmacology and therapeutics.
[42] John Anthony Bauer,et al. Pharmacodynamic Models of Nitroglycerin-Induced Hemodynamic Tolerance in Experimental Heart Failure , 1994, Pharmaceutical Research.
[43] Lewis B. Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .
[44] H. Schwilden,et al. Pharmacokinetic-pharmacodynamic modelling of the EEG effects of Ro 48-6791, a new short-acting benzodiazepine, in young and elderly subjects. , 1997, British journal of anaesthesia.
[45] L B Sheiner,et al. Kinetics of pharmacologic response. , 1982, Pharmacology & therapeutics.
[46] Lewis B. Sheiner,et al. A general conceptual model for non-steady state pharmacokinetic/Pharmacodynamic data , 2006, Journal of Pharmacokinetics and Biopharmaceutics.
[47] Jerome J. Schentag,et al. Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers , 1997, Antimicrobial agents and chemotherapy.
[48] N H Holford,et al. The Target Concentration Approach to Clinical Drug Development , 1995, Clinical pharmacokinetics.
[49] N. Holford,et al. Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man , 1984, Journal of Pharmacokinetics and Biopharmaceutics.
[50] R. Larsson,et al. A general model for time‐dissociated pharmacokinetic‐pharmacodynamic relationships exemplified by paclitaxel myelosuppression , 1998, Clinical pharmacology and therapeutics.
[51] W J Jusko,et al. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. , 1998, British journal of clinical pharmacology.
[52] M Danhof,et al. Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development , 1997, Clinical pharmacokinetics.
[53] A Bye,et al. Dynamic Modeling of Cortisol Reduction after Inhaled Administration of Fluticasone Propionate , 1996, Journal of clinical pharmacology.
[54] L B Sheiner,et al. Pharmacodynamic model of tolerance: application to nicotine. , 1988, The Journal of pharmacology and experimental therapeutics.
[55] Carl Peck,et al. An Evaluation of the Integration of Pharmacokinetic and Pharmacodynamic Principles in Clinical Drug Development , 1997, Clinical pharmacokinetics.
[56] J L Steimer,et al. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. , 1997, International journal of clinical pharmacology and therapeutics.
[57] William J. Jusko,et al. Second generation model for prednisolone pharmacodynamics in the rat , 1989, Journal of Pharmacokinetics and Biopharmaceutics.
[58] M. Gibaldi,et al. Drug distribution and pharmacologic effects , 1971 .